Skip to main content
SpringerLink
Log in

Ramelteon

A Viewpoint by Matthew W. Johnson and Roland R. Griffiths

  • Adis Drug Profile
  • Guest Commentary
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992 Jun; 44(2): 151–347

    PubMed  CAS  Google Scholar 

  2. Hajak G, Muller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003 Oct; 98(10): 1371–8

    Article  PubMed  CAS  Google Scholar 

  3. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. In press

Download references

Author information

Authors and Affiliations

  1. Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Matthew W. Johnson & Roland R. Griffiths

Authors
  1. Matthew W. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland R. Griffiths
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, M.W., Griffiths, R.R. Ramelteon. CNS Drugs 19, 1066 (2005). https://doi.org/10.2165/00023210-200519120-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200519120-00008

Search

Navigation